Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07542483 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Lebrikizumab in Adults With Nummular Eczema

Study acronym: LUMINE
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Recruitment opened Study sites: 0 to 1 · Start date changed from estimate of Apr 2026 to Apr 24, 2026v3 Show 2 more changesShow less
    • Study sites: 0 to 1
    • Start date changed from estimate of Apr 2026 to Apr 24, 2026
  2. Re-verified, no change to tracked fieldsv2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The main aim of the study is to evaluate the efficacy, safety, and tolerability of lebrikizumab treatment in adult participants with Nummular Eczema (NE) who are not adequately controlled with Topical corticosteroids (TCS) or when this treatment is not medically advisable.
Trial Details
NCT Number NCT07542483
Lead Sponsor Almirall, S.A.
Conditions Nummular Eczema
Enrollment 270 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov